<DOC>
	<DOCNO>NCT01377519</DOCNO>
	<brief_summary>This pilot randomize , blind , placebo-controlled trial noninvasive , FDA approve treatment uterine fibroid call MR Guided Focused Ultrasound ( MRgFUS ) . Our hypothesis MRgFUS provide superior relief fibroid symptom compare placebo , sham MRgFUS treatment . The investigator recruit 20 premenopausal woman symptomatic uterine fibroid participate trial . Participants randomly assign 2:1 ratio active treatment arm ( MRgFUS ) versus sham MRgFUS treatment . Participants remain blinded group assignment 3 month . After 3 month , participant tell treatment group assign sham group offer complimentary MRgFUS desire . Women exclude inappropriate candidate 3 month delay fibroid treatment , significant anemia . The investigator assess change baseline 1 3 month treatment fibroid symptom , quality life , fibroid volume measure MRI , hematocrit .</brief_summary>
	<brief_title>Magnetic Resonance Guided Focused Ultrasound Uterine Fibroids</brief_title>
	<detailed_description />
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Age &gt; 18 year Premenopausal Symptomatic fibroid Fibroids accessible focus ultrasound treatment Exclusion criterion : Desires future fertility Current pregnancy Hematocrit &lt; 30 % Emergency room visit last 3 month fibroid symptom History venous thromboembolism Fibroids : &gt; 10cm , nonenhancing contrast Adenomyosis Contraindications undergo MRI Unexplained menstrual irregularity</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Fibroids</keyword>
	<keyword>Uterine</keyword>
	<keyword>Focused Ultrasound</keyword>
	<keyword>Magnetic Resonance focus ultrasound</keyword>
	<keyword>HIFU</keyword>
	<keyword>NOninvasive</keyword>
	<keyword>Treatment</keyword>
</DOC>